Welcome to our dedicated page for NUMINUS WELLNESS news (Ticker: NUMIF), a resource for investors and traders seeking the latest updates and insights on NUMINUS WELLNESS stock.
Numinus Wellness Inc. (NUMIF) is a mental health care company dedicated to advancing traditional and innovative behavioral health treatments through safe, evidence-based psychedelic-assisted therapies. They aim to heal rather than manage symptoms of depression, anxiety, trauma, pain, and substance use. By leading the integration of psychedelic-assisted therapies into mainstream clinical practice, Numinus is pioneering a healthier society. Numinus helps individuals heal and be well by providing innovative mental health care and access to safe, evidence-based therapies.
Numinus Wellness Inc. has received Health Canada approval to provide psilocybin-assisted therapy for treatment-resistant depression, marking a significant milestone as the first such treatment outside clinical trials. This therapy will be conducted at their Montreal clinic, using synthetic psilocybin sourced from Psygen Labs. The approval allows for innovative mental health treatment under Health Canada's Special Access Program (SAP), which facilitates access to psychedelic compounds for patients who have failed conventional treatments. Numinus aims to expand its offerings in Canada, enhancing access to evidence-based psychedelic therapies.
Numinus Wellness Inc. (TSX: NUMI) (OTC: NUMIF) will participate in a fireside chat at the H.C. Wainwright Global Investment Conference on May 25, 2022, at 3:30 p.m. ET. Founder and CEO Payton Nyquvest will discuss Numinus’ innovative mental health treatments, including psychedelic-assisted therapies. Attendees can register for the event here. The chat will also be available via live webcast and archived on Numinus’ investor relations website.
Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) has mailed materials for its special meeting of shareholders scheduled for June 8, 2022. Shareholders are urged to vote by June 6. The meeting will address the proposed acquisition of Novamind Inc., which is expected to significantly enhance Numinus' revenue and profitability. Key benefits include a rapid expansion in the U.S. and an estimated C$3 million in annual cost savings. The interim court order for the transaction was granted on May 6, 2022.
Numinus Wellness Inc. (TSX: NUMI, OTCQX: NUMIF) announced its participation in key psychedelic industry conferences. Notably, at the Catalyst Summit 2022 in Kingston (May 20-22), several executives, including Michael Tan and Sharan Sidhu, will lead panel discussions. Additionally, Numinus will present at the Psychedelic Therapeutics and Drug Development Conference 2022 in Washington, DC (May 23-24), focusing on regulatory navigation. Lastly, at the From Research to Reality Summit in Toronto (May 27-29), research presentations will showcase findings on MDMA-assisted therapy and psychedelics' impact on opioid use.
Numinus Wellness (TSX: NUMI) (OTCQX: NUMIF) has announced the launch of Music As Medicine, a series of ceremonial concerts exploring the integration of music in psychedelic-assisted therapy. The initiative will feature artists like Jon Hopkins and East Forest and will take place in various cities in the U.S. and Canada, starting with an event in Los Angeles on May 21, 2022. This series aims to highlight music's role in mental health and connect communities through innovative therapeutic experiences.
Numinus Wellness reported a remarkable 240% year-over-year revenue growth to $0.8 million for Q2 2022, driven by acquisitions. Gross margin surged to 29.1% from 6.5% in Q1 2022. The company generated a gross profit of $228,759, marking a 349% increase from the prior quarter. Despite these gains, Numinus faced a loss of $7.8 million. The company concluded the quarter with $48.3 million in cash. A proposed acquisition of Novamind is anticipated to increase revenue significantly, positioning Numinus as a leader in psychedelic-assisted therapies.
Numinus Wellness Inc. (TSX: NUMI, OTCQX: NUMIF) will participate in two virtual investor conferences in April 2022. Payton Nyquvest, Founder and CEO, is scheduled to present at the Sequire Cannabis & Psychedelic Conference on April 20 at 1:00 p.m. ET and at the KCSA Psychedelics Investor Conference on April 27 at 1:00 p.m. ET. Numinus focuses on mental health care, developing and delivering innovative therapies, including psychedelic-assisted treatments. For more details, visit www.numinus.com.
Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) has initiated the first MDMA-assisted therapy session at its clinics in Montreal and Vancouver as part of the MAPPUSX clinical trial for PTSD. This study is sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS) and focuses on the safety and efficacy of MDMA-assisted psychotherapy. The Montreal site recently began drug administration under the supervision of experienced therapists. This advancement signifies Numinus's commitment to integrating psychedelic therapies into clinical practice and enhancing treatment accessibility.
Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) will participate in Maxim Group's 2022 Virtual Growth Conference from March 28-30, 2022. A presentation by Founder and CEO Payton Nyquvest will be available on-demand starting March 28 at 9:00 a.m. ET. Interested participants can register here. Numinus focuses on innovative mental health care and evidence-based psychedelic therapies aimed at addressing conditions like depression and anxiety.
Numinus Wellness Inc. (TSX: NUMI, OTCQX: NUMIF) has received approval from the Public Health Agency of Canada for a Containment Level 2 license at its Numinus Bioscience lab. This enhancement enables advanced research on natural psychedelics, focusing on studies involving Psilocybe mushrooms and their effects on the human body. The license will facilitate tests that support innovative intellectual property development and revenue generation through contract research services. The company aims to advance its psychedelic research initiatives and enhance the accessibility of psychedelic-assisted therapies.
FAQ
What is the current stock price of NUMINUS WELLNESS (NUMIF)?
What is the market cap of NUMINUS WELLNESS (NUMIF)?
What is Numinus Wellness Inc. focused on?
What is Numinus Wellness Inc.'s mission?
How does Numinus Wellness Inc. contribute to mental health care?
What sets Numinus Wellness Inc. apart from other mental health care providers?
What is the goal of Numinus Wellness Inc. in the mental health care space?
